WallStSmart

Kenvue Inc. (KVUE)vsNu Skin Enterprises Inc (NUS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Kenvue Inc. generates 1020% more annual revenue ($15.41B vs $1.38B). KVUE leads profitability with a 10.8% profit margin vs -15.7%. NUS appears more attractively valued with a PEG of 0.78. KVUE earns a higher WallStSmart Score of 58/100 (C).

KVUE

Buy

58

out of 100

Grade: C

Growth: 4.7Profit: 7.0Value: 4.0Quality: 5.0
Piotroski: 4/9Altman Z: 1.22

NUS

Hold

47

out of 100

Grade: D+

Growth: 2.0Profit: 4.5Value: 7.7Quality: 7.5
Piotroski: 5/9Altman Z: 4.45
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

KVUESignificantly Overvalued (-86.3%)

Margin of Safety

-86.3%

Fair Value

$9.95

Current Price

$19.20

$9.25 premium

UndervaluedFair: $9.95Overvalued
NUSUndervalued (+53.3%)

Margin of Safety

+53.3%

Fair Value

$21.79

Current Price

$4.79

$17.00 discount

UndervaluedFair: $21.79Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

KVUE0 strengths · Avg: 0/10

No standout strengths identified

NUS3 strengths · Avg: 9.3/10
Price/BookValuation
0.3x10/10

Reasonable price relative to book value

Altman Z-ScoreHealth
4.4510/10

Safe zone — low bankruptcy risk

PEG RatioValuation
0.788/10

Growing faster than its price suggests

Areas to Watch

KVUE3 concerns · Avg: 3.3/10
PEG RatioValuation
1.554/10

Expensive relative to growth rate

Revenue GrowthGrowth
3.0%4/10

3.0% revenue growth

Altman Z-ScoreHealth
1.222/10

Distress zone — elevated risk

NUS4 concerns · Avg: 2.5/10
Market CapQuality
$230.73M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
6.9%3/10

ROE of 6.9% — below average capital efficiency

Revenue GrowthGrowth
-17.1%2/10

Revenue declined 17.1%

EPS GrowthGrowth
-98.2%2/10

Earnings declined 98.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : KVUE

KVUE has a balanced fundamental profile.

Bull Case : NUS

The strongest argument for NUS centers on Price/Book, Altman Z-Score, PEG Ratio. PEG of 0.78 suggests the stock is reasonably priced for its growth.

Bear Case : KVUE

The primary concerns for KVUE are PEG Ratio, Revenue Growth, Altman Z-Score.

Bear Case : NUS

The primary concerns for NUS are Market Cap, Return on Equity, Revenue Growth.

Key Dynamics to Monitor

KVUE profiles as a value stock while NUS is a turnaround play — different risk/reward profiles.

NUS carries more volatility with a beta of 0.97 — expect wider price swings.

KVUE is growing revenue faster at 3.0% — sustainability is the question.

KVUE generates stronger free cash flow (549M), providing more financial flexibility.

Bottom Line

KVUE scores higher overall (58/100 vs 47/100). NUS offers better value entry with a 53.3% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Kenvue Inc.

CONSUMER DEFENSIVE · HOUSEHOLD & PERSONAL PRODUCTS · USA

Kenvue Inc. is a consumer health company globally.

Visit Website →

Nu Skin Enterprises Inc

CONSUMER DEFENSIVE · HOUSEHOLD & PERSONAL PRODUCTS · USA

Nu Skin Enterprises, Inc. develops and distributes wellness and personal care products globally. The company is headquartered in Provo, Utah.

Visit Website →

Want to dig deeper into these stocks?